Lazar Dimitrov PhD

Lazar Dimitrov serves as our Senior Vice President of Corporate Development.  He brings more than 20 years of research, investment and operational experience in the life sciences to Bright Peak.  Most recently, Lazar was the Head of Business Development at Day One Biopharmaceuticals, a precision oncology company developing targeted therapies for patients of all ages. At Day One, Lazar negotiated the exclusive global license agreement with Merck KGaA to develop and commercialize the MEK inhibitors pimasertib and MSC2015103B in 2021 and the global collaboration with Foundation Medicine to advance pediatric cancer care in 2022.   Previously, Lazar served as Principal at the leading global life sciences investment firm Clarus Ventures, which now operates as Blackstone Life Sciences.   At Clarus, Lazar sourced, led the diligence, and negotiated several venture, co-development and royalty transactions across therapeutic areas, modalities and stages of development.  He was a Board Observer at SFJ Pharmaceuticals,  Galera Therapeutics, Graybug Vision, Lumos Pharma, and Tisbury Pharmaceuticals, and a Board Member at Tropicalis Finance Company.  Before Clarus Ventures, Lazar was a scientist at Crystal Biosciences (acquired by Ligand Pharmaceuticals).  Prior to his scientific training, he was an analyst at Rho Ventures and the M&A group at Merrill Lynch.  Lazar obtained his Ph.D. in Genome Sciences from the University of Washington and conducted his postdoctoral training at UC Berkeley.  He received his B.A. in Mathematics and Economics with high honors from Dartmouth College.